LCD-L38351
Document details
Summary
The introduction of repeat germline testing under the MolDX program by Noridian may affect the reimbursement landscape for genetic testing services. Providers should ensure they are familiar with theNew guidelines for repeat germline testing could impact reimbursements.
Affected codes
ICD-10-CM
Affected specialty
Oncology alerts →Source document
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=38351&ver=9CLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA022437 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable GnRH agonist indicated for advanced prostate cancer, billing under Medicare Part B as a physician-administered drug. As an established inj
View alertPolicy FDA-NDA021288 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable approved for a new dosage form under NDA021288, placing it firmly in the Medicare Part B billing pathway as a physician-administered drug.
View alertPolicy FDA-NDA020715 · Oncology
Trelstar (triptorelin pamoate) is an intramuscular injectable indicated for prostate cancer, placing it squarely in the Medicare Part B billing pathway as a physician-administered drug. It is typicall
View alertPolicy FDA-NDA219304 · Oncology
Romvimza (vimseltinib) is an oral capsule kinase inhibitor approved via NDA219304, placing it squarely in the Medicare Part D billing pathway as a self-administered outpatient drug. As a new molecular
View alert